Skip to main content
. 2022 Aug 18;23(16):9288. doi: 10.3390/ijms23169288

Figure 8.

Figure 8

Targeting a brain tumor via nonthermal plasma in vivo, showing (A) bioluminescence imaging; (B) the region of interest levels for tumor changes following plasma treatment; (C) sectioned mouse brain tumor volume and size determined by bioluminescence imaging; and (D,E) expressions of cleaved caspase-3, p-p38, cleaved poly (ADP-ribose) polymerase (PARP), and survival, as determined by immunofluorescence [158].